Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Alfacalcidol

Alfacalcidol: A Vital Prodrug for Bone and Mineral Health

Introduction

Vitamin D plays an indispensable role in the regulation of calcium and phosphate metabolism, essential for maintaining healthy bones and teeth. Among the various vitamin D analogs, Alfacalcidol stands out due to its unique pharmacological profile and broad clinical utility. Used extensively in the treatment of conditions like osteoporosis, chronic kidney disease (CKD), and hypocalcemia, Alfacalcidol offers therapeutic advantages over conventional vitamin D supplements, particularly in patients with impaired renal function.

Alfacalcidol:

Alfacalcidol (1α-hydroxyvitamin D3) is a synthetic analog of vitamin D3. It is a prodrug that is converted in the liver to calcitriol (1,25-dihydroxyvitamin D3), the biologically active form of vitamin D.

Key Properties:

  • Chemical Formula: C27H44O2

  • Molecular Weight: 400.6 g/mol

  • Solubility: Fat-soluble

  • Brand names: One-Alpha, Alfacal, Alpha D3

Uses of Alfacalcidol:

Unlike vitamin D3 (cholecalciferol), which requires both liver and renal hydroxylation, Alfacalcidol bypasses the kidney step, making it effective in patients with chronic kidney disease, where renal conversion is impaired.

Mechanism of Action:

Alfacalcidol is converted in the liver to 1,25-dihydroxyvitamin D3 (calcitriol). Calcitriol then:

  • Increases intestinal absorption of calcium and phosphate

  • Promotes bone mineralization

  • Regulates parathyroid hormone (PTH) secretion

  • Enhances calcium reabsorption in the kidneys

Thus, Alfacalcidol addresses both hypocalcemia and secondary hyperparathyroidism, two common complications in CKD and bone disorders.

Pharmacokinetics:

Parameter Description
Absorption Rapid, oral bioavailability ~80%
Metabolism Hepatic conversion to calcitriol
Half-life 3–5 hours (effects last longer)
Excretion Primarily via bile and feces

Alfacalcidol’s rapid hepatic conversion makes it suitable for daily or intermittent dosing depending on clinical need.

Clinical Indications:

Alfacalcidol is used in a range of skeletal and mineral metabolism disorders, including:

1. Chronic Kidney Disease (CKD)

  • To treat renal osteodystrophy and secondary hyperparathyroidism

  • Effective across all CKD stages, including dialysis patients

2. Osteoporosis

  • Especially in elderly patients with low vitamin D levels

  • Improves bone mineral density (BMD) and reduces fracture risk

3. Rickets and Osteomalacia

  • Nutritional or hypophosphatemic causes

  • Corrects vitamin D-dependent bone deformities

4. Hypoparathyroidism

  • Used to maintain calcium levels in the absence of PTH

5. Post-parathyroidectomy Hypocalcemia

  • Helps stabilize calcium post-operatively

Dosage and Administration:

Formulations:

  • Capsules: 0.25 mcg, 1 mcg

  • Drops: 2 mcg/mL

  • Injections: IV/IM for hospital settings

Typical Dosages:

Condition Dose Range (Oral)
CKD (non-dialysis) 0.25 – 1 mcg daily
Hemodialysis patients 0.5 – 1 mcg IV 2–3 times/week
Osteoporosis 0.25 – 1 mcg daily
Hypoparathyroidism 0.5 – 2 mcg daily

Note: Always titrate based on serum calcium and phosphate levels.

Monitoring Parameters:

  • Serum Calcium: To prevent hypercalcemia

  • Phosphate: To avoid soft tissue calcification

  • PTH (in CKD): To monitor response

  • Renal Function Tests: eGFR, serum creatinine

Monitoring is especially critical in dialysis patients, who are at increased risk of calcium-phosphate imbalance.

Clinical Evidence and Studies:

Osteoporosis:

  • Studies show Alfacalcidol reduces vertebral and hip fractures in elderly women

  • Improves BMD and muscle strength, reducing fall risk

CKD:

  • Effective in reducing PTH levels

  • Better tolerated than calcitriol in terms of hypercalcemia incidence

Meta-analysis:

  • Compared to native vitamin D, Alfacalcidol leads to quicker correction of deficiency

  • Ideal for patients with hepatic conversion capacity intact but renal dysfunction

Comparison with Other Vitamin D Analogs:

Parameter Alfacalcidol Calcitriol Cholecalciferol
Activation Site Liver Already active Liver + Kidney
Use in CKD Yes Yes Less effective
Hypercalcemia Risk Moderate Higher Lower
Onset of Action Fast Fast Slow

Alfacalcidol offers a balanced safety-efficacy profile, making it a preferred agent in many cases.

Adverse Effects:

Though generally well-tolerated, overuse or improper monitoring can lead to complications:

Common Side Effects:

  • Hypercalcemia

  • Hyperphosphatemia

  • Nausea, vomiting

  • Headache

  • Fatigue

Rare but Serious:

  • Soft tissue or vascular calcification

  • Nephrocalcinosis

  • Arrhythmias due to calcium imbalance

Symptoms of toxicity: polyuria, polydipsia, anorexia, muscle weakness, confusion

Drug Interactions:

Interacting Agent Effect
Thiazide diuretics Increased risk of hypercalcemia
Antacids (aluminum-based) Aluminum toxicity in CKD
Digitalis glycosides Enhanced cardiotoxicity with hypercalcemia
Magnesium-containing drugs Risk of hypermagnesemia

Counseling Point: Avoid self-medication with over-the-counter calcium or magnesium supplements.

Special Populations:

Pregnancy and Lactation:

  • Category C

  • Use only if clearly needed; monitor calcium closely

Pediatrics:

  • Safe under physician supervision

  • Used in pediatric rickets

Geriatrics:

  • Excellent choice for elderly due to high absorption and efficacy

  • Monitor for falls and muscle weakness

Patient Counseling Points:

Educating patients about proper use and monitoring is crucial:

  • Take at same time daily, with or without food

  • Avoid high calcium diet or supplements unless advised

  • Report symptoms of high calcium: fatigue, constipation, thirst

  • Adhere to regular lab testing

Storage and Stability:

  • Store below 25°C (77°F)

  • Protect from light and moisture

  • Keep out of reach of children

Alfacalcidol in Global Guidelines:

  • KDIGO Guidelines (Kidney Disease Improving Global Outcomes):

    • Recommend vitamin D analogs like Alfacalcidol in CKD-MBD (mineral bone disorder) management when PTH levels are high

  • NICE Guidelines (UK):

    • Approve Alfacalcidol for osteoporosis and CKD management, especially when standard vitamin D fails

  • ISCD (International Society for Clinical Densitometry):

    • Recommends vitamin D analogs in high-risk osteoporotic patients

Conclusion:

Alfacalcidol has become a mainstay in the management of bone mineral disorders, especially in patients with renal impairment or secondary hyperparathyroidism. Its unique advantage of liver-only activation allows it to sidestep renal limitations, offering a safe and potent alternative to both native vitamin D and calcitriol. With a well-established safety profile, robust efficacy, and ease of use, Alfacalcidol continues to improve the quality of life for patients with osteoporosis, CKD, rickets, and hypoparathyroidism. However, like all vitamin D analogs, it requires careful monitoring to avoid adverse outcomes. For healthcare providers and patients alike, Alfacalcidol represents the intersection of biochemical precision and therapeutic convenience — a key tool in the long-term maintenance of skeletal and mineral health.

References:

  1. KDIGO 2017 Clinical Practice Guidelines for CKD-MBD

  2. Lips P, et al. (2003). Alfacalcidol and fracture prevention.

  3. NICE Clinical Guidelines: Osteoporosis and CKD

  4. Holick MF. (2007). Vitamin D Deficiency.

  5. Compston J. (2009). Vitamin D analogs in osteoporosis treatment.